Citations

Showing 10 of 108015 citations.

Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour
Lee, Jen‐Chieh , Jeng, Yung‐Ming , Su, Sheng-Yao, Wu, Chen‐Tu , Tsai, Keh‐Sung , Lee, Cheng‐Han , Lin, Chung‐Yen , Carter, Jodi M. , Huang, Jenq‐Wen , Chen, Shu-Hwa, Shih, Shyang‐Rong , Mariño‐Enríquez, Adrián , Chen, Chih-Chi, Folpe, Andrew L. , Chang, Yih‐Leong , Liang, Cher‐Wei , Chen, Shu‐Hwa , Marino-Enriquez, Adrian , Carter, Jodi

Mayo Clinic

The Journal of Pathology | October 16, 2014 | Volume: 235 | Issue: 4 | Pages: 539-545

10.1002/path.4465 | PMID 25319834 Get It

Abstract Phosphaturic mesenchymal tumours ( PMTs ) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour‐induced osteomalacia ( TIO ) through secretion of phosphatonins including fibroblast growth factor 23 ( FGF23 ). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1–FGFR1 fusion gene in three out of four PMTs by next‐generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT‐PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1–FGFR1 fusion out of an additional 11 PMTs . Overall, nine out of 15 PMTs (60%) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia‐inducing FGFR1 fusion genes, which are ligand‐independent, the FN1–FGFR1 chimeric protein was predicted to preserve its ligand‐binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Identifying Patients in the Acute Psychiatric Hospital Who May Benefit From a Palliative Care Approach
Burton, M. Caroline , Warren, Mark, Cha, Stephen S., Stevens, Maria , Blommer, Megan, Kung, Simon , Cha, Stephen S., Lapid, Maria I.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | October 16, 2014 | Volume: 33 | Issue: 3 | Pages: 228-232

10.1177/1049909114554795 | PMID 25318929 Get It

Identifying patients who will benefit from a palliative care approach is the first critical step in integrating palliative with curative therapy. Criteria are established that identify hospitalized medical patients who are near end of life, yet there are no criteria with respect to hospitalized patients with psychiatric disorders. The records of 276 consecutive patients admitted to a dedicated inpatient psychiatric unit were reviewed to identify prognostic criteria predictive of mortality. Mortality predictors were 2 or more admissions in the past year ( P = .0114) and older age ( P = .0006). Twenty-two percent of patients met National Hospice and Palliative Care Organization noncancer criteria for dementia. Palliative care intervention should be considered when treating inpatients with psychiatric disorders, especially older patients who have a previous hospitalization or history of dementia.
Automated Recommendation for Cervical Cancer Screening and Surveillance
MacLaughlin, Kathy L. , Casey, Petra M., Kastner, Thomas M., Henry, Michael , Hankey, Ronald A., Peters, Steve G. , Greenes, Robert A. , Chaudhry, Rajeev , Wagholikar, Kavishwar B. , Henry, Michael R, Chute, Christopher G. , Liu, Hongfang

Mayo Clinic

Cancer Informatics | October 15, 2014 | Volume: 13s3 | Issue: No issue available | Pages: CIN.S14035

10.4137/cin.s14035 | PMID 25368505 Get It

Because of the complexity of cervical cancer prevention guidelines, clinicians often fail to follow best-practice recommendations. Moreover, existing clinical decision support (CDS) systems generally recommend a cervical cytology every three years for all female patients, which is inappropriate for patients with abnormal findings that require surveillance at shorter intervals. To address this problem, we developed a decision tree-based CDS system that integrates national guidelines to provide comprehensive guidance to clinicians. Validation was performed in several iterations by comparing recommendations generated by the system with those of clinicians for 333 patients. The CDS system extracted relevant patient information from the electronic health record and applied the guideline model with an overall accuracy of 87%. Providers without CDS assistance needed an average of 1 minute 39 seconds to decide on recommendations for management of abnormal findings. Overall, our work demonstrates the feasibility and potential utility of automated recommendation system for cervical cancer screening and surveillance.
Hepatology: Portal vein cavernoma imitating cholangiocarcinoma in a patient with erythropoietic protoporphyria
Saberi, Behnam , Deurdulian, Corinne, Pandya, Himani , Kahn, J.M.

Mayo Clinic

Journal of Gastroenterology and Hepatology | October 15, 2014 | Volume: 29 | Issue: 10 | Pages: 1755-1755

10.1111/jgh.12729 | PMID 25318384 Get It

Hitting the wall: glycogen, glucose and the carotid bodies
Joyner, Michael J. , Limberg, Jacqueline K. , Joyner, Michael J

Mayo Clinic

The Journal of Physiology | October 15, 2014 | Volume: 592 | Issue: 20 | Pages: 4413-4414

10.1113/jphysiol.2014.281790 | PMID 25320155 Get It

Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa
Thienemann, Friedrich , Dzudié, Anastase , Mocumbi, Ana Olga , Blauwet, Lori A., Sani, Mahmoud U. , Karaye, Kamilu M. , Ogah, Okechukwu S. , Mbanze, Irina, Mbakwem, Amam , Udo, Patience, Tibazarwa, Kemi, Ibrahim, Ahmed S., Burton, Rosie , Stewart, Simon , Blauwet, Lori, Damasceno, Albertino , Sliwa, Karen , Mbakwem, Amam

Mayo Clinic

BMJ Open | October 15, 2014 | Volume: 4 | Issue: 10 | Pages: e005950

10.1136/bmjopen-2014-005950 | PMID 25763797 Get It

Introduction Pulmonary hypertension (PH) is a devastating, progressive disease with increasingly debilitating symptoms and usually shortened overall life expectancy due to a narrowing of the pulmonary vasculature and consecutive right heart failure. Little is known about PH in Africa, but limited reports suggest that PH is more prevalent in Africa compared with developed countries due to the high prevalence of risk factors in the region. Methods and analysis A multinational multicentre registry-type cohort study was established and tailored to resource-constraint settings to describe disease presentation, disease severity and aetiologies of PH, comorbidities, diagnostic and therapeutic management, and the natural course of PH in Africa. PH will be diagnosed by specialist cardiologists using echocardiography (right ventricular systolic pressure >35 mm Hg, absence of pulmonary stenosis and acute right heart failure), usually accompanied by shortness of breath, fatigue, peripheral oedema and other cardiovascular symptoms, ECG and chest X-ray changes in keeping with PH as per guidelines (European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines). Additional investigations such as a CT scan, a ventilation/perfusion scan or right heart catheterisation will be performed at the discretion of the treating physician. Functional tests include a 6 min walk test and the Karnofsky Performance Score. The WHO classification system for PH will be applied to describe the different aetiologies of PH. Several substudies have been implemented within the registry to investigate specific types of PH and their outcome at up to 24 months. Data will be analysed by an independent institution following a data analyse plan. Ethics and dissemination All local ethics committees of the participating centres approved the protocol. The data will be disseminated through peer-reviewed journals at national and international conferences and public events at local care providers.
Regulation of FSP27 protein stability by AMPK and HSC70
Zhang, Xiaodong , Heckmann, Bradlee L. , Xie, Xitao, Saarinen, Alicia M., Liu, Jun , Liu, Jun Qi , Liu, Jun

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | October 15, 2014 | Volume: 307 | Issue: 11 | Pages: E1047-E1056

10.1152/ajpendo.00125.2014 | PMID 25315694 Get It

Fat-specific protein 27 (FSP27) plays a pivotal role in controlling the formation of large lipid droplet and energy metabolism. The cellular levels of FSP27 are tightly regulated through the proteasomal ubiquitin-mediated degradation. However, the upstream signals that trigger FSP27 degradation and the underlying mechanism(s) have yet to be identified. Here we show that AMP-activated protein kinase (AMPK) activation by AICAR (5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide) or phenformin induced the ubiquitination of FSP27 and promoted its degradation in 3T3-L1 adipocytes. The levels of FSP27 protein could be maintained by either knocking down AMPKα1 or blocking proteasomal pathway. Moreover, AICAR treatment induced multilocularization of LDs in 3T3-L1 adipocytes, reminiscent of the morphological changes in cells depleted of FSP27. Furthermore, mass spectrometry-based proteomic analysis identified heat shock cognate 70 (HSC70) as a novel binding protein of FSP27. The specific interaction was confirmed by co-immunoprecipitation of both ectopically expressed and endogenous proteins. Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR. However, silencing of the E3 ubiquitin ligase CHIP (COOH terminus of HSC70-interacting protein) failed to alter the stability of FSP27 protein under both conditions. Taken together, our data indicate that AMPK is a negative regulator of FSP27 stability through the proteasomal ubiquitin-dependent protein catabolic process. Promotion of FSP27 degradation may be an important factor responsible for the beneficial effect of AMPK activators on energy metabolism.
What Fraction of Medicaid Enrollees Have Private Insurance Coverage at the Time of Enrollment? Estimates from Administrative Data
Dague, Laura , DeLeire, Thomas , Friedsam, Donna, Leininger, Lindsey , Meier, Sarah , Voskuil, Kristen

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | October 14, 2014 | Volume: 51 | Issue: No issue available | Pages: No page available

10.1177/0046958014544020 | PMID 25316718 Get It

We use administrative data from Wisconsin to determine the fraction of new Medicaid enrollees who have private health insurance at the time of enrollment in the program. Through the linkage of several administrative data sources not previously used for research, we are able to observe coverage status directly for a large fraction of enrollees and indirectly for the remainder. We provide strict bounds for the percentages in each status and find that the percentage of new enrollees with private insurance coverage at the time of enrollment lies between 16 percent and 29 percent, and the percentage that dropped private coverage in favor of public insurance lies between 4 percent and 18 percent. Our point estimates indicate that, among all new enrollees, 21 percent had private health insurance at the time of enrollment and that 10 percent dropped this coverage. Our results show substantially lower rates than previous studies of crowd-out following public health insurance expansions and significant rates of dual coverage, whereby new enrollees into public insurance retain their previously held private insurance coverage.
A Longitudinal Medical School Evidence-Based Medicine Curriculum
Jaeger, Thomas M. , McDonald, Furman S., West, Colin P.

Mayo Clinic

MedEdPORTAL | October 14, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.9827 Get It

Evidence and the Practice of Prosthodontics: 20 Years after EBD Introduction
Carr, Alan B.

Mayo Clinic

Journal of Prosthodontics | October 14, 2014 | Volume: 24 | Issue: 1 | Pages: 12-16

10.1111/jopr.12232 | PMID 25313687 Get It

AbstractProsthodontics has a rich history related to the principles embedded in evidence‐based health care. This paper reviews the evidence‐based prosthodontics activity over the past 3 decades. It also discusses the impact of health care reform on evidence‐based medicine as it relates to broader context of care outcomes. Finally, the value associated with an Evidence Stewardship emphasis in prosthodontics is presented. This emphasis suggests that combining evidence from clinical trials with evidence from clinical practice environments best equips clinicians for the management of patients in the future. Adoption of a strategic Evidence Stewardship direction is an extended commitment to change that recognizes health care reform aims and seeks to be an accountable provider group in the broader health care arena. The vision to form a representative network of prosthodontic practitioners that augments a commitment to Cochrane “clinical trial” data demonstrates a responsibility to professional transparency about who we are, adds value for patients and oral health care providers, impacts teachers and students in dental education, and provides a measure of care accountability unique in dentistry.